Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Jat, Kana R ^a   Walia, Dinesh K ^b   Khairwa, Anju ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ITRACONAZOLE; OMALIZUMAB; PLACEBO; ANTIALLERGIC AGENT; ANTIFUNGAL AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEVER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEMOPTYSIS; HOSPITALIZATION; HUMAN; HYPOKALEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; INJECTION SITE WARMTH; INTESTINE OBSTRUCTION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SPUTUM LEVEL; SYSTEMATIC REVIEW; THORAX PAIN; VOMITING; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; COMPLICATION; EARLY TERMINATION OF CLINICAL TRIAL;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CYSTIC FIBROSIS; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; ITRACONAZOLE; OMALIZUMAB; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964694992     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010288.pub3     Document Type: Review

References (38)

1. Novartis . An exploratory study to assess multiple doses of Omalizumab in patients with cystic fibrosis complicated by acute bronchopulmonary aspergillosis (ABPA). Clinicaltrials.gov (www.clinicaltrials.gov) (accessed 21/01/2013) 2008:ClinicalTrials.gov Identifier: NCT00787917. [CRS: 5500100000010742]
2. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009;135(3):805-26.
3. Becker JW, Burke W, McDonald G, Greenberger PA, Henderson WR, Aitken ML. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996;109(6):1536-40.
4. Brinkmann F, Schwerk N, Hansen G, Ballmann M. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010;65(1):134-5.
5. Costa CAC, Moreira LAC, Marcos AS, Santos SMAP. Prevalence of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis in the state of Bahia, Brazil. Jornal Brasileiro De Pneumologia: Publication Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia 2008;34(11):900-6.
6. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. Journal of Clinical Investigation 1997;99(5):879-87.
7. Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
8. Elphick H, Southern K. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD002204.pub3]
9. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 1997;155(6):1828-34.
10. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. Journal of Pediatrics 2008;153(2):S4-S14.
11. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999;116(3):639-46.
12. Greenberger PA. Allergic bronchopulmonary aspergillosis. Journal of Allergy and Clinical Immunology 2002;110(5):685-92.
13. Hemmann S, Nikolaizik WH, Schöni MH, Blaser K, Crameri R. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. European Journal of Immunology 1998;28(4):1155-60.
14. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
15. Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
16. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2004;34(4):632-8.
17. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatric Pulmonology 2008;43(12):1249-51.
18. Knutsen AP. Lymphocytes in allergic bronchopulmonary aspergillosis. Frontiers in Bioscience: A Journal and Virtual Library 2003;8:589-602.
19. Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clinical & Developmental Immunology 2011 Apr 5 [Epub ahead of print].
20. Lebecque P, Leonard A, Argaz M, Godding V, Pilette C. Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Reports 2009;pii:bcr07.2008.0379. [DOI: 10.1136/bcr.07.2008.0379]
21. Mastella G, Rainisio M, Harms HK, Hodson ME, Koch C, Navarro J, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology 2000;16(3):464-71.
22. Nelson LA, Callerame ML, Schwartz RH. Aspergillosis and atopy in cystic fibrosis. American Review of Respiratory Disease 1979;120(4):863-73.
23. Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999;115(2):364-70.
24. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. Journal of Allergy and Clinical Immunology 2006;117(6):1493-9.
25. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003559.pub4]
26. Patterson R, Greenberger PA, Radin RC, Roberts M. Allergicbronchopulmonaryaspergillosis: staging as an aid to management. Journal of Laboratory and Clinical Medicine 1982;99(2):288-93.
27. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
28. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Annals of Internal Medicine 1977;86(4):405-14.
29. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. New England Journal of Medicine 2005;352(19):1992-2001.
30. Shields RL, Whether WR, Zioncheck K, O'Connell L, Fendly B, Presta LG, et al. Inhibition of allergic reactions with antibodies to IgE. International Archives of Allergy and Immunology 1995;107(1-3):308-12.
31. Skov M, McKay K, Koch C, Cooper PJ. Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respiratory Medicine 2005;99(7):887-93.
32. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2003;37 Suppl 3:S225-64.
33. Taccetti G, Procopio E, Marianelli L, Campana S. Allergic bronchopulmonary aspergillosis in Italian cystic fibrosis patients: prevalence and percentage of positive tests in the employed diagnostic criteria. European Journal of Epidemiology 2000;16(9):837-42.
34. Tillie-Leblond I, Tonnel A-B. Allergic bronchopulmonary aspergillosis. Allergy 2005;60(8):1004-13.
35. Valletta EA, Braggion C, Mastella G. Sensitization to aspergillus and allergic bronchopulmonary aspergillosis in a cystic fibrosis population. Pediatric Asthma, Allergy & Immunology 1993;7(1):43-9.
36. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007;62(3):276-7.
37. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatric Pulmonology 2008;43(6):607-10.
38. Jat KR, Walia DK, Khairwa A. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.CD010288.pub2]